Medical Challenge

  • Influenza is a highly virulent disease that can affect every person, with different severity grades
  • Besides limited seasonal outbreaks (epidemics), the infection can lead to devastating worldwide outbreaks (pandemics)
  • Current drugs have a limited efficacy especially when not administered shortly after the infection, are not effective against co-infections and resistance is a rising issue
  • Thus, there is an urgent need for novel broadly active anti-influenza drugs that overcome the problem of resistance

Atriva‘s Approach to a de-risked and rapid Development

ATRIVA focuses on repurposing existing so-called MEK-inhibitors, originally used in oncology, which are already marketed or have undergone clinical investigations.

ATRIVA scientists are leading experts for influenza viruses. They found that virus replication is dependent on a specific cellular pathway, which can be effectively blocked by MEK-inhibitors.

MEK-inhibitors have a larger therapeutic time window than existing anti-influenza drugs without inducing resistance (compared to Tamiflu) and suppress dangerous bacterial co-infections of the lungs as proven in extensive pre-clinical studies of ATRIVA scientists. The risk of side effects is negligible, due to short therapeutic intervention of 5 to maximal 7 days.

MEK inhibitors

Unique Advantages vs. existing Approaches

  • Prolonged therapeutic activity against influenza infection even up to four days post infection, compared to Tamiflu
  • Broad activity against circulating and newly emerging influenza viruses
  • MEK inhibitors show significant activity against bacterial co-infections (unlike Tamiflu)
  • Risk of resistance is negligible since the virus cannot replace the missing cellular function. - AND -
  • Atriva owns strong and broad IP on envisaged usage of selected candidates and combinations with full “Freedom-to-operate”
  • Short development time of the drug since data for toxicity and bioavailability are already known from the clinically proven drugs